Overview

Phase I/IIa Study of FIXFc in Hemophilia B Patients

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess safety of FIXFc at doses ranging from 1 to 100 IU/kg.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Bioverativ Therapeutics Inc.
Collaborators:
Swedish Orphan Biovitrum
Syntonix Pharmaceuticals, Inc.